This article was originally published in The Gray Sheet
Executive SummaryForms subsidiary ECM Pharma to "develop medical devices and pharmaceutically active compounds based upon natural components of the extracellular matrix," the firm reports. ECM Pharma's initial plans are to "supply cell-produced human collagen...for evaluation, testing, and ultimate use in medical devices, drug delivery, research, and manufacturing." The subsidiary, based in Organogenesis' Canton, Massachusetts facility, "expects to license issued and pending" patent applications for "production of cultured human collagen" and "the assembly of collagen into various forms and shapes"
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.